J&J Submits Dapoxetine NDA For Premature Ejaculation
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is waiting to see if the selective serotonin reuptake inhibitor will receive priority review. Submission is slightly earlier than expected.
You may also be interested in...
Dapoxetine Early 2006 Launch Expectations Premature, J&J Says
Johnson & Johnson does not expect FDA approval of its premature ejaculation therapy dapoxetine in time for an early 2006 launch
Dapoxetine Early 2006 Launch Expectations Premature, J&J Says
Johnson & Johnson does not expect FDA approval of its premature ejaculation therapy dapoxetine in time for an early 2006 launch
Adult SSRI Use And Suicidality To Get FDA Advisory Committee Review, J&J Says
A committee will meet within the next few months to review selective serotonin reuptake inhibitors and suicidality in adults, J&J Senior VP Waldstreicher says. The company’s NDA for the SSRI dapoxetine is pending; J&J is seeking to differentiate the premature ejaculation agent from the rest of the class.